At the Hart of Pathology
Sitting Down With... John Hart, Professor and Vice Chair of Anatomic Pathology at the University of Chicago Medicine
By
Helen Bristow
April 27, 2026
Clinical Scorecard: At the Hart of Pathology
At a Glance
Category Detail
Condition Hepatitis C and drug-induced liver injury Key Mechanisms Molecular techniques including next-generation sequencing (NGS) and HLA typing Target Population Patients with liver diseases and those at risk for drug-induced liver injury Care Setting Pathology laboratories and academic medical centers
Key Highlights
Hepatitis C has transitioned from a prevalent condition to one that is largely eradicated due to advancements in treatment. Molecular pathology is transforming the diagnosis of liver diseases and inflammatory GI conditions. Next-generation sequencing (NGS) has revealed genetic susceptibility to drug reactions. HLA typing helps identify patients at risk for adverse reactions to drugs and herbal supplements. The fellowship program fosters the next generation of leaders in GI and liver pathology. Guideline-Based Recommendations
Diagnosis
Utilize molecular techniques for the diagnosis of liver diseases. Management
Counsel patients on drug and supplement avoidance based on HLA typing results. Monitoring & Follow-up
Regularly assess patients for liver function and potential drug-induced injuries. Risks
Identify genetic predispositions to drug reactions to mitigate risks. Patient & Prescribing Data
Individuals with liver diseases and those on medications with known hepatotoxic potential.
Understanding genetic factors can guide safer prescribing practices.
Clinical Best Practices
Incorporate molecular pathology techniques into routine diagnostics. Engage in continuous education and training for fellows and residents. Foster collaboration and knowledge exchange within the pathology community. References
